Defining & Designing Patient-Centric Doses
What is patient centricity? This panel will take a comprehensive look at the definition of patient centricity from varying perspectives within the drug development value chain. From the regulatory, commercial drug formulation, and academic viewpoints, what does patient centricity mean and how do these perspectives feed into the broader meaning of the term?
Don't miss the panel discussion Tuesday, 19 October 10am EST | 4pm CET.
Introducing UltraBurst, a novel, innovative excipient platform for ODTs. Delivering the fastest disintegration time of any preformulated products on the market while maintaining best in class hardness, friability, and API loading.
Pharmaburst® is the global standard for orally disintegrating dosage forms. It is fully optimized to deliver superior organoleptics and robust, rapidly disintegrating tablets.
Pharmasperse® is specifically engineered for the ready manufacture of orally dispersible powder (ODP) formulations intended for filling into sachets or stickpacks.
Advantol® 300 is a leading-edge drug delivery system for the development of soft-chew tablets.
Our Actimask® technology provides an excellent taste barrier and mouth feel without hindering API release and onset of therapeutic relief. By incorporating our taste-masking technology in the development of your product, we can help you increase the chances for success throughout your product life cycle.